The guideline for the management of hepatocellular carcino-ma (HCC) was first developed in 2003 and revised in 2009 by the Korean Liver Cancer Study Group and the National Cancer Center, Korea. Since then, many studies on HCC have been carried out in Korea and other countries. In particular, a substantial body of knowledge has been accumulated on diagnosis, staging, and treatment specific to Asian charac-teristics, especially Koreans, prompting the proposal of new strategies. Accordingly, the new guideline presented herein was developed on the basis of recent evidence and expert opinions. The primary targets of this guideline are patients with suspicious or newly diagnosed HCC. This guideline pro-vides recommendations for the initial treatm...
[[abstract]]The most recent version of the European Society for Medical Oncology (ESMO) Clinical Pra...
Primary liver cancer, most of which is hepatocellular carcinoma (HCC), is the third common leading c...
Background/Aims: Considering the high prevalence and mortality of hepatocellular carcinoma (HCC) in ...
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and r...
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and r...
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and r...
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth most common c...
Hepatocellular carcinoma (HCC) is one of the major cancers with a high incidence and mortality in Ko...
Hepatocellular carcinoma (HCC) is a highly prevalent disease in many Asian countries, accounting for...
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality ...
Hepatocellular carcinoma (HCC) is a highly malignant cancer and third major cause of death in Korean...
Hepatocellular carcinoma (HCC), characterized by insidious onset, rapid progression, and poor treatm...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidel...
Asia has a disproportionately large share of the world's hepatocellular carcinoma (HCC), mainly beca...
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer and the 5 year survi...
[[abstract]]The most recent version of the European Society for Medical Oncology (ESMO) Clinical Pra...
Primary liver cancer, most of which is hepatocellular carcinoma (HCC), is the third common leading c...
Background/Aims: Considering the high prevalence and mortality of hepatocellular carcinoma (HCC) in ...
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and r...
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and r...
The guideline for the management of hepatocellular carcinoma (HCC) was first developed in 2003 and r...
Hepatocellular carcinoma (HCC) is the fifth most common cancer globally and the fourth most common c...
Hepatocellular carcinoma (HCC) is one of the major cancers with a high incidence and mortality in Ko...
Hepatocellular carcinoma (HCC) is a highly prevalent disease in many Asian countries, accounting for...
Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality ...
Hepatocellular carcinoma (HCC) is a highly malignant cancer and third major cause of death in Korean...
Hepatocellular carcinoma (HCC), characterized by insidious onset, rapid progression, and poor treatm...
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidel...
Asia has a disproportionately large share of the world's hepatocellular carcinoma (HCC), mainly beca...
Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer and the 5 year survi...
[[abstract]]The most recent version of the European Society for Medical Oncology (ESMO) Clinical Pra...
Primary liver cancer, most of which is hepatocellular carcinoma (HCC), is the third common leading c...
Background/Aims: Considering the high prevalence and mortality of hepatocellular carcinoma (HCC) in ...